Navigation Links
Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical,Potential

Single-Dose Oral Ty800 Vaccine Immunogenic & Well-Tolerated in NIH-Sponsored Phase 1/2 Study

NEEDHAM, MA (May 18, 2007) - AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today positive preliminary results from an investigational double-blind, placebo-controlled Phase 1/2 dose-escalating clinical trial of its typhoid fever vaccine candidate, Ty800, in healthy volunteers. The researchers found the single-dose, oral vaccine to be well tolerated and immunogenic, with over 90% of vaccinated subjects generating immune responses. Based on these excellent results, AVANT plans to further develop Ty800 to compete in the expanding typhoid fever vaccine market, which currently has over $200 million in annual sales. AVANT plans to initiate its own sponsored Phase 2 dose-ranging trial of Ty800 in mid-2007.

“Typhoid fever remains endemic in many developing areas of the world, as well as being an important potential health threat for travelers and military personnel in areas affected by the disease,” said Dr. Mitchell B. Cohen, Principal Investigator in the study and Director of Gastroenterology, Hepatology and Nutrition at Cincinnati Children’s Hospital Medical Center. “The development of an effective and practical vaccine for all ages will provide an important tool for controlling this disease. A safe typhoid fever vaccine that can be easily administered could significantly reduce the morbidity and mortality associated with typhoid fever.”

“We are delighted with these results for our single-dose, oral Ty800 vaccine candidate,” said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. “These results indicate that AVANT’s vaccine may have significant potential advantages over the currently licensed vaccines, which offer limited protection rates of 50-80% and require either a single needle injection or three to four oral doses over the course o
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Avants Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
2. SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
9. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
10. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
11. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
Post Your Comments:
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
(Date:7/30/2015)... ... 2015 , ... As more hospitals across the country see the value in ... challenge. Because of growing competition, it is more important than ever to market ... The team at Wound Care Advantage has found that while many hospitals ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating coach Simone Myers ... for women interested in improving their love lives using specific "lines" designed to ... to the public early this morning, has drawn praise from several dating and ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. ... health care technology vendors, will take place May 14-17, 2016 in Minneapolis, MN. ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a ... San Bernardino, recently announced that the Centers for Medicare and Medicaid (CMS) have awarded ... health care providers. 24/7 Care At Home’s agency is one of three top Orange ...
(Date:7/30/2015)... ... , ... Ross A. Clevens, MD, FACS has been reappointed by ... Surgery. This is Dr. Clevens’ second appointment by the prestigious school. Over ... strong presence and a valuable mentoring program for medical students. , ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3
... The following is a,statement in response to Patrick Swayze ... CEO of the Pancreatic Cancer,Action Network, the only national ... support, community outreach and,advocacy for a cure., "We ... with,pancreatic cancer and our thoughts go out to him ...
... WASHINGTON and NEWARK, N.J., March 5 Besler,& ... principal, Philip,Besler, have agreed to pay the United ... fraud against the federal Medicare program, the,Justice Department ... the North Brunswick,N.J.-headquartered company counseled hospital clients to ...
... MINNEAPOLIS, March 5 As two of the ... implementation of the Freedom,to Breathe Act, we are ... denounced so-called "theatrical performances" in bars as a,violation ... Freedom to Breathe Act was passed to protect ...
... could use,a little pampering now and then. Think your mom ... Breast Cancer Coalition,(PBCC) and Doneckers of Ephrata take care of ... in 250 words or less why your mom, as a,breast ... and you and your mom could be in for a ...
... says , , WEDNESDAY, March 5 (HealthDay News) -- Variations ... warfarin are important in determining the initial doses of ... is being put to medical use. Last August, the ... say that doctors should consider a genetic test when ...
... Spheris, a leading global,provider of clinical documentation technology and ... results for the fourth quarter,ended December 31, 2007., ... fourth quarter of,2007 after the close of market trading ... call on Thursday, March 27, 2008, at 8:00 a.m. ...
Cached Medicine News:Health News:Patrick Swayze's Diagnosis With Pancreatic Cancer: a Statement From the Pancreatic Cancer Action Network 2Health News:New Jersey Healthcare Consulting Firm to Pay U.S. $2.875 Million to Resolve Allegations of Medicare Fraud 2Health News:Leading Health Groups Strongly Support the Minnesota Department of Health's Efforts to Enforce Freedom to Breathe Act 2Health News:The Pennsylvania Breast Cancer Coalition Announces Last Chance to Enter 'Makeover for Mom' Contest 2Health News:Genetic Test Predicts Response to Warfarin 2Health News:Genetic Test Predicts Response to Warfarin 3
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: